Exosome-based therapeutics
for regenerative medicine

Unlocking the exosome revolution across
multiple disease indications

Building a pipeline through scalable
and reproducible exosome biology

Two lead therapeutic candidates toward
clinical development
Tackling inflammatory diseases and organ regeneration
10x increase in
production yield in
a
tenth of the time
Multi-step proprietary approach improving formulation

EVerZom mission:

Turning exosome science into therapies

The challenge

Exosomes are natural cell-derived vesicles with immunomodulatory and regenerative properties. 
To accelerate clinical translation and therapeutic diffusion, one challenge need to be adress: 
the manufacturing.

About Exosomes →

Scale-Up
Standardization
Clinical Translation

EVerZom technology

EVerZom combines proprietary manufacturing and formulation technologies designed for scalable, reproducible, and clinical-grade exosome therapeutics.

Our platform →

5 patents
GMP certified
x10 yield & speed
10L scale bioreactors

EverGel

EverGel is our lead therapeutic candidate advancing toward clinical development for fistula healing in Crohn’s disease. We are expanding our technology across other regenerative applications.

Pipeline →

Preclinical POC
2027 First in Human
Validated regulatory toxicological studies

Pipeline

EVerGel

Complex perianal fistula

  1. Discovery
  2. PoC
  3. CTA enabling
  4. Phase 1/2a
  5. Phase 3

Naïve exosomes + thermoresponsive hydrogel for digestive tissue healing

EViv

Acute on chronic liver failure (ACLF)

  1. Discovery
  2. PoC
  3. CTA enabling
  4. Phase 1/2a
  5. Phase 3

Naïve exosomes intravenous for organ regeneration

Discover our pipeline

Latest news

Partner with us to accelerate the next
generation of exosome-based therapies.

Contact Us